EW
Edwards Lifesciences Corporation
NYSEUSDEQUITY
Healthcare
DELAYED
Neutral
+14/100
Last price
86.48
▼ 0.75 (0.86%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
87.55
Prev close
87.23
Day high
87.88
Day low
85.94
Volume
3.38M
Market cap
$49.85B
P/E (TTM)
51.48
52W range
72.30 – 96.29
Day trading desk
Gap from prior close
+0.37%
Prior close 87.23
VWAP
86.79
-0.36% from price
Relative volume
1.98×
Unusually busy
Session range
3.40%
85.94 – 88.86
Position in range
18%
Near session low
ATR (14D)
1.90
2.19% of price
Prior day high
87.57
PDH
Prior day low
85.34
PDL
Bid / ask spread
—
Quote not published
Session volume
7.59M
Avg 3.83M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.82%
-3.8%
1M
-3.80%
-5.0%
3M
-7.65%
-12.2%
6M
+6.98%
-11.2%
YTD
+1.44%
-12.8%
1Y
+12.21%
-4.2%
3Y
+24.83%
-57.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on EW open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+274.09K
Net buying
Buy transactions
34
421.79K shares
Sell transactions
21
147.70K shares
Net transactions
+55
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
1.12M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 11, 26 | LIPPIS DANIEL J Officer |
SELL | 619 | $54.17K | Direct |
| Sep 11, 26 | LIPPIS DANIEL J Officer |
CONVERSION | 619 | $44.99K | Direct |
| Aug 31, 26 | DAHL ANDREW M Officer |
SELL | 544 | $49.53K | Direct |
| Aug 28, 26 | BRULS ANNETTE Officer |
SELL | 2.64K | $237.91K | Direct |
| Aug 26, 26 | CHOPRA DAVEEN Officer |
SELL | 31.80K | $2.89M | Direct |
| Aug 26, 26 | CHOPRA DAVEEN Officer |
CONVERSION | 31.80K | $2.31M | Direct |
| Aug 26, 26 | MARKOWITZ WAYNE Officer |
SELL | 1.24K | $113.42K | Direct |
| Aug 11, 26 | LIPPIS DANIEL J Officer |
SELL | 619 | $56.97K | Direct |
| Aug 11, 26 | LIPPIS DANIEL J Officer |
CONVERSION | 619 | $44.99K | Direct |
| Jul 30, 26 | MARKOWITZ WAYNE Officer |
SELL | 146 | $12.59K | Direct |
| Jul 28, 26 | MARKOWITZ WAYNE Officer |
SELL | 9.63K | $818.96K | Direct |
| Jul 28, 26 | MARKOWITZ WAYNE Officer |
CONVERSION | 9.63K | $712.66K | Direct |
| Jul 27, 26 | ZOVIGHIAN BERNARD J Chief Executive Officer |
STOCK | 319 | $0 | Direct |
| Jul 27, 26 | ZOVIGHIAN BERNARD J Chief Executive Officer |
SELL | 2.92K | $245.13K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOBO DONALD E JR |
Officer | — | Sale |
CHOPRA DAVEEN |
Officer | 44.32K | Sale |
GALLAHUE KIERAN T. |
Director | 83.97K | Stock Award(Grant) |
LIPPIS DANIEL J |
Officer | 40.03K | Sale |
LORANGER STEVEN R |
Director | 84.37K | Stock Award(Grant) |
MISTRAS THEODORA |
Chief Financial Officer | 99.92K | Stock Award(Grant) |
ULLEM SCOTT B |
Chief Financial Officer | 313.06K | Conversion of Exercise of derivative security |
VALERIANI NICHOLAS J |
Director | 84.42K | Stock Award(Grant) |
WOOD LARRY L |
Officer | 207.05K | Sale |
ZOVIGHIAN BERNARD J |
Chief Executive Officer | 111.49K | Stock Gift |
Fundamentals
Market cap$49.85B
Enterprise value$46.41B
Revenue (TTM)$6.51B
Gross profit$5.07B
EBITDA$2.00B
Net income$979.90M
EPS (TTM)$1.68
Free cash flow$1.23B
Total cash$4.25B
Total debt$704.40M
Book value / share$18.42
Shares outstanding576.40M
Float574.49M
Short % of float1.79%
Dividend yield0.00%
Beta (5Y)0.86
Valuation & profitability ratios
Trailing P/E51.48
Forward P/E25.60
PEG ratio1.86
Price / sales—
Price / book4.70
EV / revenue7.13
EV / EBITDA23.24
Gross margin77.84%
Operating margin29.84%
Profit margin15.43%
Return on equity9.18%
Return on assets8.37%
Debt / equity6.57
Current ratio4.52
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $6.07B | $5.44B | $5.01B | $4.46B | +11.5% |
| Operating revenue | $6.07B | $5.44B | $5.01B | $4.46B | +11.5% |
| Cost of revenue | $1.33B | $1.12B | $978.40M | $723.70M | +19.4% |
| Gross profit | $4.73B | $4.32B | $4.03B | $3.74B | +9.5% |
| Research & development | $1.08B | $1.05B | $962.90M | $843.60M | +2.5% |
| Selling, general & admin | $2.09B | $1.79B | $1.58B | $1.36B | +16.5% |
| Total operating expense | $3.10B | $2.84B | $2.55B | $2.20B | +9.0% |
| Operating income | $1.64B | $1.48B | $1.49B | $1.54B | +10.5% |
| Net interest income | $148.40M | $100.50M | $49.60M | $16.30M | +47.7% |
| Pre-tax income | $1.27B | $1.55B | $1.37B | $1.52B | -17.8% |
| Tax provision | $216.90M | $152.10M | $152.40M | $195.50M | +42.6% |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | -74.3% |
| Net income to common | $1.07B | $4.17B | $1.40B | $1.52B | -74.3% |
| Basic EPS | 1.84 | 6.98 | 2.31 | 2.46 | -73.6% |
| Diluted EPS | 1.83 | 6.97 | 2.30 | 2.44 | -73.7% |
| EBIT | $1.29B | $1.57B | $1.39B | $1.54B | -17.5% |
| EBITDA | $1.45B | $1.72B | $1.53B | $1.68B | -15.9% |
| Basic shares | 584.80M | 597.70M | 606.70M | 619.00M | -2.2% |
| Diluted shares | 585.80M | 599.30M | 609.40M | 624.20M | -2.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $2.94B | $3.05B | $1.13B | $769.00M | -3.5% |
| Cash & short-term investments | $4.23B | $3.98B | $1.63B | $1.22B | +6.3% |
| Accounts receivable | $659.60M | $609.10M | $771.50M | $643.00M | +8.3% |
| Inventory | $1.13B | $1.09B | $903.50M | $875.50M | +3.6% |
| Total current assets | $6.74B | $6.29B | $4.04B | $3.10B | +7.2% |
| Property, plant & equipment | $1.91B | $1.78B | $1.68B | $1.73B | +7.3% |
| Goodwill & intangibles | $2.90B | $2.95B | $1.54B | $1.45B | -1.9% |
| Total assets | $13.70B | $13.06B | $9.36B | $8.29B | +4.9% |
| Total current liabilities | $1.81B | $1.51B | $1.20B | $1.02B | +20.5% |
| Long-term debt | $598.30M | $597.70M | $597.00M | $596.30M | +0.1% |
| Total debt | $705.40M | $700.00M | $685.10M | $691.30M | +0.8% |
| Total liabilities | $3.36B | $2.99B | $2.64B | $2.49B | +12.3% |
| Retained earnings | $14.24B | $13.17B | $8.99B | $7.59B | +8.2% |
| Shareholder equity | $10.34B | $10.00B | $6.65B | $5.81B | +3.4% |
| Working capital | $4.93B | $4.78B | $2.84B | $2.07B | +3.0% |
| Net tangible assets | $7.44B | $7.05B | $5.11B | $4.36B | +5.6% |
| Shares issued | 658.70M | 654.80M | 650.50M | 646.30M | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | -74.4% |
| Depreciation & amortisation | $156.60M | $155.20M | $144.90M | $139.60M | +0.9% |
| Stock-based compensation | $158.10M | $162.30M | $139.40M | $126.80M | -2.6% |
| Change in working capital | $154.60M | -$259.30M | -$526.30M | -$421.40M | +159.6% |
| Operating cash flow | $1.60B | $542.30M | $895.80M | $1.22B | +194.2% |
| Capital expenditure | -$260.20M | -$282.40M | -$266.30M | -$264.80M | +7.9% |
| Investing cash flow | -$712.90M | $2.31B | $173.80M | $252.30M | -130.8% |
| Share buybacks | -$893.40M | -$1.16B | -$879.60M | -$1.73B | +22.9% |
| Financing cash flow | -$956.80M | -$983.00M | -$711.00M | -$1.58B | +2.7% |
| Free cash flow | $1.33B | $259.90M | $629.50M | $953.40M | +413.7% |
| End cash position | $2.94B | $3.06B | $1.15B | $772.60M | -3.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | +5.6% |
| Operating revenue | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | +5.6% |
| Cost of revenue | $392.40M | $362.60M | $343.00M | $345.20M | $344.40M | +8.2% |
| Gross profit | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | +4.9% |
| Research & development | $278.90M | $263.30M | $267.70M | $280.70M | $276.20M | +5.9% |
| Selling, general & admin | $561.20M | $522.20M | $602.90M | $514.60M | $502.00M | +7.5% |
| Total operating expense | $829.10M | $771.30M | $856.30M | $782.80M | $756.90M | +7.5% |
| Operating income | $519.50M | $514.70M | $370.30M | $425.10M | $430.90M | +0.9% |
| Net interest income | $30.00M | $33.50M | $35.90M | $38.60M | $37.40M | -10.4% |
| Pre-tax income | $519.80M | — | — | — | — | — |
| Tax provision | $278.40M | $78.30M | $26.20M | $56.10M | $64.30M | +255.6% |
| Net income | $241.90M | $380.70M | $91.20M | $291.10M | $333.20M | -36.5% |
| Net income to common | $241.90M | $380.70M | $91.20M | $291.10M | $333.20M | -36.5% |
| Basic EPS | 0.42 | 0.66 | 0.16 | 0.50 | 0.57 | -36.4% |
| Diluted EPS | 0.42 | 0.66 | 0.16 | 0.50 | 0.56 | -36.4% |
| EBIT | $519.50M | $514.70M | $27.40M | $425.10M | $430.90M | +0.9% |
| EBITDA | $562.20M | $555.60M | $70.10M | $464.30M | $469.00M | +1.2% |
| Basic shares | 576.40M | 579.20M | 580.40M | 584.70M | 587.00M | -0.5% |
| Diluted shares | 577.60M | 580.70M | 581.80M | 585.70M | 587.90M | -0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.91B | $2.45B | $2.94B | $2.69B | $3.27B | +18.9% |
| Cash & short-term investments | $4.25B | $3.67B | $4.23B | $3.84B | $4.06B | +15.8% |
| Accounts receivable | $770.40M | $775.70M | $659.60M | $693.30M | $697.00M | -0.7% |
| Inventory | $1.13B | $1.12B | $1.13B | $1.14B | $1.14B | +1.1% |
| Total current assets | $6.82B | $6.23B | $6.74B | $6.36B | $6.58B | +9.5% |
| Property, plant & equipment | $1.94B | $1.92B | $1.91B | $1.84B | $1.83B | +1.0% |
| Goodwill & intangibles | $3.33B | $3.05B | $2.90B | $2.90B | $2.95B | +9.4% |
| Total assets | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | +4.1% |
| Total current liabilities | $1.51B | $1.41B | $1.81B | $1.59B | $1.40B | +7.0% |
| Long-term debt | $598.70M | $598.50M | $598.30M | $598.20M | $598.00M | +0.0% |
| Total debt | $704.40M | $702.90M | $705.40M | $700.30M | $702.60M | +0.2% |
| Total liabilities | $3.14B | $2.99B | $3.36B | $3.07B | $2.88B | +5.0% |
| Retained earnings | $14.86B | $14.62B | $14.24B | $14.15B | $13.86B | +1.7% |
| Shareholder equity | $10.62B | $10.33B | $10.34B | $10.21B | $10.55B | +2.8% |
| Working capital | $5.31B | $4.82B | $4.93B | $4.77B | $5.17B | +10.2% |
| Net tangible assets | $7.28B | $7.28B | $7.44B | $7.31B | $7.60B | +0.1% |
| Shares issued | 576.60M | 660.00M | 658.70M | 658.20M | 657.60M | -12.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $241.40M | $380.70M | $91.20M | $290.30M | $331.50M | -36.6% |
| Depreciation & amortisation | $42.70M | $40.90M | $42.70M | $39.20M | $38.10M | +4.4% |
| Stock-based compensation | $42.20M | $45.40M | $39.20M | $41.20M | $37.50M | -7.0% |
| Change in working capital | $131.90M | -$501.50M | $254.30M | $192.70M | -$141.70M | +126.3% |
| Operating cash flow | $651.90M | $43.80M | $450.90M | $573.70M | $290.20M | +1,388.4% |
| Capital expenditure | -$66.90M | -$64.90M | -$97.40M | -$57.50M | -$49.30M | -3.1% |
| Investing cash flow | -$193.20M | -$92.80M | -$198.30M | -$427.80M | -$172.10M | -108.2% |
| Share buybacks | -$153.30M | -$421.80M | -$40.60M | -$588.70M | -$5.50M | +63.7% |
| Financing cash flow | -$300.00K | -$451.20M | -$11.40M | -$740.10M | $52.70M | +99.9% |
| Free cash flow | $585.00M | -$21.10M | $353.50M | $516.20M | $240.90M | +2,872.5% |
| End cash position | $2.91B | $2.45B | $2.94B | $2.69B | $3.29B | +18.9% |
Options analytics
Put / call volume
0.06
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
75.00
-13.3% from spot
ATM implied vol
1.6%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
313
Contracts, this expiry
Put volume
18
Contracts, this expiry
Heaviest call OI
75.00
0 contracts
Heaviest put OI
75.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.74 | 0.78 | +5.1% |
| Mar 2026 | 0.73 | 0.78 | +7.3% |
| Dec 2025 | 0.62 | 0.58 | -6.3% |
| Sep 2025 | 0.59 | 0.67 | +12.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.74 | 23 | $1.68B | +8.0% |
| Next quarter | 0.71 | 23 | $1.70B | +8.3% |
| Current year | 3.00 | 27 | $6.76B | +11.5% |
| Next year | 3.38 | 27 | $7.43B | +9.9% |
Analyst targets & ownership
Mean target$101.64
High target$110.00
Low target$84.00
Implied upside17.53%
Analyst count25
ConsensusBUY
Strong buy / Buy4 / 18
Hold6
Sell / Strong sell0 / 0
Held by insiders0.19%
Held by institutions95.61%
Institutions holding1.92K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
86.41
+0.08% from price
SMA 20
86.78
-0.35% from price
SMA 50
88.64
-2.44% from price
SMA 100
87.96
-1.69% from price
SMA 200
85.15
+1.57% from price
EMA 12
86.70
-0.25% from price
EMA 26
87.38
-1.03% from price
EMA 50
87.80
-1.51% from price
RSI (14)
46.4
Neutral
MACD (12,26,9)
-0.68
Hist -0.01
ATR (14)
1.90
2.19% of price
Realised vol 30D
23.5%
Annualised
Bollinger upper
89.41
20, 2σ
Bollinger lower
84.15
20, 2σ
50 / 200 cross
Golden
88.64 vs 85.15
Trend bias
Above 200
+1.57%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.56
Less volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
23.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-13.2%
Peak to trough
Max drawdown 5Y
-54.3%
Peak to trough
ATR 14
1.90
2.19% of price
Beta (reported)
0.86
5Y monthly, from filing
Short interest
Shares short
9.09M
Prior 10.24M
Change vs prior
-11.3%
Shorts covering
% of float
1.79%
Normal
% of shares out
1.58%
Against total outstanding
Days to cover
3.2
Liquid
Float
574.49M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 11, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 25, 26 | Leerink Partners | UPGRADE | Market Perform | Outperform |
| Jul 24, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jul 24, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jul 16, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| Jul 15, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jul 13, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 8, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 6, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Jun 30, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 16, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jun 2, 26 | TD Cowen | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split3:1
Split dateJun 1, 2020
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-28
Periodic Financial Reports
10-Q · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-23
Annual report of employee stock purchase
11-K · 2026-06-12
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-27
Corporate Changes & Voting Matters
8-K · 2026-05-08
Periodic Financial Reports
10-Q · 2026-05-06
Corporate Changes & Voting Matters
8-K · 2026-05-04
Headlines
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $102 From $100, Keeps Outperform Rating
MT Newswires · 2d ago
Edwards Lifesciences to Host Investor Event in Conjunction With TCT
Business Wire · 2d ago
JPMorgan Adjusts Price Target on Edwards Lifesciences to $105 From $100, Keeps Overweight Rating
MT Newswires · 5d ago
Edwards Lifesciences Says US FDA Approves AUTUS Pediatric Pulmonary Valve
MT Newswires · 5d ago
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
Business Wire · 5d ago
Edwards Lifesciences' TAVR Evaluation in Moderate Aortic Stenosis Among Most Awaited Clinical Trial Readouts, Oppenheimer Says
MT Newswires · 7d ago
How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions
Simply Wall St. · 18d ago
Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion
Simply Wall St. · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.